Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors

Sponsor

Westfälische Wilhelms-Universität Münster (Other)

Overall Status

Recruiting

CT.gov ID

NCT04738162

Collaborator

photonamic GmbH & Co. KG (Industry), medac GmbH (Industry)

Enrollment

Locations

Arm

30.2

Anticipated Duration (Months)

13.3

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this prospective, open, single-armed, multicenter, phase II study for application of 5-ALA in children and adolescents with supratentorial brain tumors 80 patients will be investigated.

Primary objective of the study is to determine the safety of 5-ALA for fluorescence-guided resections in children and adolescents with supratentorial, intra-axial brain tumors.

Secondary objectives are

to determine whether fluorescent tissue truly signifies tumor (positive predictive value) in various pediatric brain tumors
to determine the degree of tumor resection on early post-operative MRI
and to determine the pharmacokinetics of 5-ALA in this population.

Condition or Disease	Intervention/Treatment	Phase
Brain Tumor, Pediatric	Drug: 5-Aminolevulinic Acid Hydrochloride, Oral	Phase 2

Detailed Description

In 2007, 5-aminolevulinic acid (5-ALA) was approved in Europe by the European Medicines Agency (EMA) (brand name: Gliolan®) for "the visualization of malignant tissue during surgery for malignant glioma (WHO III and IV) in adults." Similarly, approval for 5-ALA was granted by the FDA in 2017 as an "optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery" (brand name: Gliolan®). Goal of the study is to investigate if the use of 5-ALA is safe in children and get preliminary information on the type of paediatric brain tumors which are suitable for fluorescence-guided resection with 5-ALA.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

80 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors

Actual Study Start Date :

Sep 25, 2020

Anticipated Primary Completion Date :

Apr 1, 2023

Anticipated Study Completion Date :

Apr 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 5-Aminolevulinic Acid (5-ALA) Application of 5-ALA oral solution followed by fluorescence-guided brain tumor resection	Drug: 5-Aminolevulinic Acid Hydrochloride, Oral Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible Other Names: Gliolan

Arm

Intervention/Treatment

Experimental: 5-Aminolevulinic Acid (5-ALA)

Application of 5-ALA oral solution followed by fluorescence-guided brain tumor resection

Drug: 5-Aminolevulinic Acid Hydrochloride, Oral

Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible

Other Names:

Gliolan

Outcome Measures

Primary Outcome Measures

Safety of 5-ALA for fluorescence-guided resections in children and adolescents determined as incidence of adverse events of CTCAE grade III-V. [up to 6 weeks after tumor resection]
Incidence of adverse events of CTCAE grade III, IV or V (excluding chemotherapy-associated toxicities) during and after 5-ALA fluorescence-guided resections in children and adolescents

Secondary Outcome Measures

True positive rate of fluorescence for indicating tumor [Day 0: during the surgery]
Biopsies will be taken during tumor resection. The true positive rate of 5 ALA induced fluorescence for three different tumor regions, i.e. the number of fluorescing tumor samples containing tumor cells divided by the number of all tumor samples from 1) the tumor bulk, 2) the border area and 3) the suspected infiltration zone. A stratification will be performed depending on whether surgery is for newly diagnosed or recurrent tumor.
Determination of the percentage of patients with gros total resection and subtotal resection [up to 72h after surgery]
For every patient in whom a complete resection of enhancing tumor is expected a priori, it will be assessed whether there is residual contrast-enhancement or not on early post-operative MRI. The volume of contrast-enhancing tumor on early post-operative MRI (up to 72h after surgery) in cm3 will be determined. If the volume is < 0.175cm3, the patient will be classified as "gros total resection". If the volume is >0.175cm3, the patient will be classified as "subtotal resection". Percentage of patients for both groups will be determined.
Correlation of residual contrast-enhancing tumor with residual fluorescence after surgery [Day 0: during the surgery]
For both groups (patients with gros total and subtotal resection) the percentage of patients with residual fluorescence at end of surgery, as determined during the surgery by the operating surgeon (yes/no), will be calculated.
Determination of protoporphyrin IX (PPIX) in serum to analyse AUC (Area under the curve) of PPIX [3-6 hours, 6-9 hours and 9-12 hours after surgery]
The investigators aim to determine 5-ALA pharmacokinetics in children and adolescents from PPIX plasma levels in order to assess if the pharmacokinetics differ between adults and children. Pharmacokinetic data will be analyzed using population pharmacokinetic software approach using nonlinear-mixed effects modelling (NONMEM). In order to assess if the pharmacokinetics are similar, the area under the curve (AUC) for PPIX as a measure of 5-ALA exposure will be calculated. For this purpose protoporphyrin IX will be measured in serum 3 times within 12h after 5-ALA-administration.
Determination of protoporphyrin IX (PPIX) in serum to determine interpolated maximum plasma concentration (Cmax) of PPIX. [3-6 hours, 6-9 hours and 9-12 hours after surgery]
Protoporphyrin IX will be measured in serum 3 times within 12h after 5-ALA-administration. Pharmacokinetic data will be analyzed using population pharmacokinetic software approach using nonlinear-mixed effects modelling (NONMEM). Using the model, interpolated maximum plasma concentration (Cmax) of PPIX will be determined for every patient.

Eligibility Criteria

Criteria

Ages Eligible for Study:

3 Years to 17 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 3 - <18 years
First radiological diagnosis of intra-axial, supratentorial contrast-enhancing tumor on MRI or recurrent supratentorial intra-axial brain tumor (malignant glioma, astrocytoma, malignant ependymoma, atypical teratoid rhabdoid tumors (AT/RT), Oligodendroglioma, etc.)
Resection is part of therapeutic strategy with an emphasis on neurological safety
Informed consent by the parents or guardians and if possible assent of the patient after education of purpose and risks of study. Patients that are able to understand should provide assent to participate in the trial
Female adolescents: not pregnant (pregnancy test required for adolescents of child-bearing age) and not breast-feeding (for at least 24 hours after Gliolan intake). Female patients of childbearing potential and male patients who are sexually active must be practising a highly effective method of birth control up to 6 weeks after the tumor operation consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials.

Exclusion Criteria:

Posterior fossa tumors
Extra-axial tumors such as craniopharyngioma
Germ cell tumor or entities precluding surgical resection
Acute or chronic porphyria
Hypersensitivity to 5-ALA or porphyrins
Renal insufficiency: serum creatinine > 2x upper limit of normal (ULN)
Hepatic insufficiency: serum bilirubin > 2x ULN, serum γ-glutamyl transferase > 2,5 x ULN, alanine transaminase (ALT) and aspartate transaminase (AST)> 2,5 ULN
Blood clotting: INR (international normalized ratio) out of acceptable limits
Other malignant disease
Patients with pre-existing cardiovascular diseases
Co-administration with other potentially phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts)
Planned administration of potentially hepatotoxic substances within 24 hours after 5-ALA administration

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Universitätsklinikum Augsburg, Klinik für Neurochirurgie	Augsburg	Germany	86146
2	Universitätsklinikum Essen, Klinik für Neurochirurgie	Essen	Germany	45147
3	Universitätsmedizin Mainz, Klinik und Poliklinik für Neurochirurgie	Mainz	Germany	55131
4	Neurochirurgische Klinik der Universität München (LMU)	München	Germany	81377
5	University Hospital Münster, Klinik für Neurochirurgie	Münster	Germany	48149
6	Universitätsklinikum Tübingen, Klinik für Neurochirurgie	Tübingen	Germany	72076